Fujifilm Diosynth Biotechnologies to establish new viral vector manufacturing facility in Boston
The $40 million investment marks the company's third viral vector manufacturing site
Fujifilm is investing 4 billion yen ($40 million) in its contract development and manufacturing organization (CDMO), Fujifilm Diosynth Biotechnologies, to build a new process development and manufacturing facility for viral vectors and advanced therapies in the greater-Boston area.
The new facility, which represents the third location for viral vector CDMO services provided by Fujifilm Diosynth Biotechnologies, is scheduled to begin process development operations in autumn 2021.
The company's decision to expand manufacturing capacity comes as a direct response to the growing viral vector sector, which is focused on using genes to treat or prevent disease.
The new facility will house experimental and analytical equipment for viral vector and advanced therapy process development, with contract manufacturing services for early phase clinical trials beginning at the site in fall 2023.
The CDMO chose the greater-Boston area to establish its new site for its high concentration of biopharmaceutical companies and academia innovating in the field of advanced therapies.
In 2014, Fujifilm Corporation established viral vector manufacturing offering at the Fujifilm Diosynth Biotechnologies’ site in Texas, US. As the market for viral vectors has continued to expand, Fujifilm has invested a further 13 billion yen (approx. $120 million) in the Texas site to build a new process development facility and to expand existing manufacturing facilities.
More recently, in October last year, Fujifilm Diosynth Biotechnologies announced an investment to provide process and analytical development, and cGMP manufacturing of viral vectors in the UK.
“Together these three sites will enable us to respond to our customers’ needs to support their viral vector manufacturing process from early clinical stage through to commercialization, to ensure these life-saving treatments are available to patients in need,” said Martin Meeson, Chief Executive Officer, Fujifilm Diosynth Biotechnologies.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance